Novartis signs $1Bn deal for GSK’s Multiple Sclerosis Antibody

24/08/2015 - 2 minutes

Is this Novartis‘ next blockbuster? The Swiss company has acquired GlaxoSmithKline‘s (GSK) immunosuppressive antibody Ofatumumab for up to $1Bn. The new drug allows Novartis to enter the multiple sclerosis market for the third time.

Earlier this year, Novartis purchased GSK’s oncology portfolio for $16 billion (€14Bn), including the fully human monoclonal anitbody Ofatumumab, which is already on the market for the treatment of leukemia.

Today, the Swiss giant announced that it will also buy all the remaining indications for this drug, with a special focus on multiple sclerosis in mind. On that account, Novartis will pay $300 million (€266M) upfront, $200 million (€178M) to start a phase III and further $534 million (€473M) milestone payments are waiting for GSK during its way to the market. In any future sales, the latter would receive  12% of royalties.

How does the drug work?

Patients suffering from relapsing remitting multiple sclerosis frequently experience inflammatory attacks that damage the brain and its neurological functions.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!